Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

marvessa Jul. 4 at 11:28 AM

$IMUX somewhere here should be the bottom

1 · Reply

Paulfrench Jul. 4 at 6:28 AM

$IMUX It would seem that we have reversal signals with two crossings of the Kaufmann Mobile Mobile 10 in a row ... We will have to think about buying (in my opinion)

1 · Reply

Old_Man_59 Jul. 3 at 5:48 PM

$IMUX Have a great 4th but take it easy on the fireworks!!

0 · Reply

JackLarson369 Jul. 3 at 3:42 PM

$IMUX Jan 26 2.5c activity. taking note, starter @.73

0 · Reply

skuntmonkey Jul. 3 at 3:36 PM

$IMUX going to load up for the future, adding 10k shares, hoping for future big bucks

0 · Reply

gertje1954 Jul. 3 at 3:21 PM

$IMUX

0 · Reply

Jw242 Jul. 3 at 3:17 PM

$IMUX

0 · Reply

Old_Man_59 Jul. 3 at 2:40 PM

$IMUX Vidofludimus calcium shows benefits for most RRMS patients: Trial https://share.google/fcSgS7Quoa2heiYu5

0 · Reply

imux Jul. 3 at 7:56 AM

$IMUX It's time to go. $7.7 ★

1 · Reply

cbowers8171 Jul. 3 at 2:45 AM

$IMUX lets get back to a dollar. 💪 your pipeline is too strong for all this nonsense

1 · Reply

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 24 days ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 4 weeks ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 4 weeks ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 4 weeks ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 5 weeks ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 5 weeks ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 2 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 2 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 2 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 3 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 3 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 3 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 4 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 4 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 4 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 5 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 6 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 7 months ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 8 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 8 months ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 8 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 8 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 8 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 9 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 10 months ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 10 months ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 11 months ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 11 months ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 11 months ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Feb 22, 2024, 3:38 PM EST - 1 year ago

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Jan 5, 2024, 6:35 AM EST - 1 year ago

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Jan 5, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Nov 21, 2023, 6:30 AM EST - 1 year ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

Nov 14, 2023, 10:53 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2023 Earnings Call Transcript

marvessa Jul. 4 at 11:28 AM

$IMUX somewhere here should be the bottom

1 · Reply

Paulfrench Jul. 4 at 6:28 AM

$IMUX It would seem that we have reversal signals with two crossings of the Kaufmann Mobile Mobile 10 in a row ... We will have to think about buying (in my opinion)

1 · Reply

Old_Man_59 Jul. 3 at 5:48 PM

$IMUX Have a great 4th but take it easy on the fireworks!!

0 · Reply

JackLarson369 Jul. 3 at 3:42 PM

$IMUX Jan 26 2.5c activity. taking note, starter @.73

0 · Reply

skuntmonkey Jul. 3 at 3:36 PM

$IMUX going to load up for the future, adding 10k shares, hoping for future big bucks

0 · Reply

gertje1954 Jul. 3 at 3:21 PM

$IMUX

0 · Reply

Jw242 Jul. 3 at 3:17 PM

$IMUX

0 · Reply

Old_Man_59 Jul. 3 at 2:40 PM

$IMUX Vidofludimus calcium shows benefits for most RRMS patients: Trial https://share.google/fcSgS7Quoa2heiYu5

0 · Reply

imux Jul. 3 at 7:56 AM

$IMUX It's time to go. $7.7 ★

1 · Reply

cbowers8171 Jul. 3 at 2:45 AM

$IMUX lets get back to a dollar. 💪 your pipeline is too strong for all this nonsense

1 · Reply

Whyasking Jul. 2 at 9:47 PM

$IMUX !

0 · Reply

michele1twits Jul. 2 at 9:25 PM

$IMUX

0 · Reply

StocktwitsNews Jul. 2 at 3:14 PM

Immunic to Participate in Investor, Scientific and Industry Conferences in June $IMUX https://stocktwits.com/news/others/business/immunic-to-participate-in-investor-scientific-and-industry-conferences-in-june/chF0oTSRTww

0 · Reply

StocktwitsNews Jul. 2 at 3:12 PM

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering $IMUX https://stocktwits.com/news/others/business/immunic-inc-announces-closing-of-oversubscribed-65-million-underwritten-public-offering/chF0oGmRTwv

0 · Reply

StocktwitsNews Jul. 2 at 3:10 PM

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS $IMUX https://stocktwits.com/news/others/business/immunic-announces-completion-of-enrollment-for-both-phase-3-ensure-trials-in-relapsing-ms-and-presents-additional-data-underlining-positive-outcome-of-phase-2-calliper-trial-in-progressive-ms/chF08ziRTwH

0 · Reply

StocktwitsNews Jul. 2 at 3:08 PM

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis $IMUX https://stocktwits.com/news/others/business/immunic-reports-new-positive-long-term-open-label-extension-data-from-phase-2-em-ph-asis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple-sclerosis/chF08DVRTwu

0 · Reply

master_yan Jul. 2 at 12:31 PM

$IMUX Up 4/10's of a penny!!!!

0 · Reply

cbowers8171 Jul. 2 at 12:25 PM

$IMUX Looking forward to the “multi pronged plan” results… what do you all think that actually is?

0 · Reply

Share54321 Jul. 2 at 12:24 PM

$IMUX IMUX IMUX IMUX

0 · Reply

Jw242 Jul. 1 at 8:10 PM

$IMUX 14 red days in a row 🤟

2 · Reply

Jw242 Jul. 1 at 3:35 PM

$IMUX added 10% more under $0.70 Let’s do this

4 · Reply

threeputt213 Jul. 1 at 2:43 PM

$IMUX next catalyst? thanks

0 · Reply

Market Cap	68.32M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	635,500
Avg Vol	1,959,482
Day's Range	N/A - N/A
Shares Out	95.82M
Stochastic %K	52%
Beta	1.49
Analysts	Strong Sell
Price Target	$10.54